Tadao Ishida

681 total citations
8 papers, 10 citations indexed

About

Tadao Ishida is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Tadao Ishida has authored 8 papers receiving a total of 10 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 5 papers in Oncology and 1 paper in Molecular Biology. Recurrent topics in Tadao Ishida's work include Multiple Myeloma Research and Treatments (7 papers), CAR-T cell therapy research (2 papers) and Peptidase Inhibition and Analysis (2 papers). Tadao Ishida is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), CAR-T cell therapy research (2 papers) and Peptidase Inhibition and Analysis (2 papers). Tadao Ishida collaborates with scholars based in Japan, Taiwan and United Kingdom. Tadao Ishida's co-authors include Osamu Hosoya, Jun Shimizu, Rafaël Fonseca, Hitoshi Sawada, Kenshi Suzuki, Naoki Takezako, Yu Abe, Aravind Ramakrishnan, Taku Kikuchi and Chia-Jen Liu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Internal Medicine.

In The Last Decade

Tadao Ishida

5 papers receiving 10 citations

Peers

Tadao Ishida

ONCOL

HEMAT

IMMUN

MB

NEURO

Irene Bodega‐Mayor Spain

José J. Rifón Roca Spain

Paula Keskula United States

Graziella Bosco Spain

Chi-Wan Chow United States

Atif Asrar Japan

Alba Cabirta Spain

Amber Bahr United States

Devin McAvoy United States

Lena Oßwald Germany

Irene Bodega‐Mayor Spain

Tadao Ishida

6 ×1.0

ONCOL

3 ×1.0

HEMAT

3 ×1.0

IMMUN

2 ×1.0

MB

0 ×0.0

NEURO

Citations per year, relative to Tadao Ishida Tadao Ishida (= 1×) peers Irene Bodega‐Mayor

Countries citing papers authored by Tadao Ishida

Since Specialization

Citations

This map shows the geographic impact of Tadao Ishida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tadao Ishida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tadao Ishida more than expected).

Fields of papers citing papers by Tadao Ishida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tadao Ishida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tadao Ishida. The network helps show where Tadao Ishida may publish in the future.

Co-authorship network of co-authors of Tadao Ishida

This figure shows the co-authorship network connecting the top 25 collaborators of Tadao Ishida. A scholar is included among the top collaborators of Tadao Ishida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tadao Ishida. Tadao Ishida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Kikuchi, Taku, Nobuhiro Tsukada, Hitoshi Sawada, et al.. (2025). Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma. Transplant Infectious Disease. 27(4). e70040–e70040. 3 indexed citations

2.

Chen, Wenming, Chor Sang Chim, Wee Joo Chng, et al.. (2025). Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group. PubMed. 7(3). 36–59.

3.

Chen, Wenming, Chor Sang Chim, Wee Joo Chng, et al.. (2025). Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group. PubMed. 7(2). 1–19.

4.

Pianko, Matthew J., Charlotte Pawlyn, Shang‐Yi Huang, et al.. (2024). MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 144(Supplement 1). 4743–4743.

5.

Sborov, Douglas W., Charlotte Pawlyn, Tadao Ishida, et al.. (2024). Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9.. Journal of Clinical Oncology. 42(16_suppl). 7522–7522. 1 indexed citations

6.

Fonseca, Rafaël, Junya Kuroda, Tadao Ishida, et al.. (2022). MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 40(16_suppl). TPS8068–TPS8068. 4 indexed citations

7.

Ishida, Tadao. (2022). [Future therapeutic strategies for multiple myeloma].. PubMed. 63(6). 635–645. 1 indexed citations

8.

Okabe, Shingo, et al.. (2022). Development of Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome after Conversion from Plasmacytoma of Bone to Multiple Myeloma. Internal Medicine. 62(3). 475–479. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact